Insiders who reported open-market trades in the last 12 months at the companies Helen Torley files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Matthew L. Posard - $2.61M in HALO purchases and sales in the last 12 months
Cortney Caudill - $1.96M in HALO purchases and sales in the last 12 months
Helen Torley is a corporate insider, tracked as PRESIDENT AND CEO, Director of HALOZYME THERAPEUTICS, INC. (HALO). InsiderAlpha holds 22 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Helen Torley submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Helen Torley been buying or selling stock?
Recorded transactions: 0 open-market purchases and 125 open-market sales ($62.36M) across all tracked filings.
Helen Torley is PRESIDENT AND CEO, Director of HALOZYME THERAPEUTICS, INC. (HALO). 22 SEC Form 4 filings on record going back to 2024, most recently on 8 October 2026. Most recent open-market trade: sold $22K of HALO on 8 October 2026. Lifetime open-market sales: $62.36M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Helen Torley.
InsiderAlpha's records for Helen Torley go back to 2024: 22 primary Form 4 filings, an average of 7.3 per year. 170 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
